Benefits and Drawbacks of the Use of Oral Fluoropyrimidines as Single-Agent Therapy in Advanced Colorectal Cancer

This publication has 4 references indexed in Scilit:

• Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial
  Journal of Clinical Oncology, 2004
• XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2004
• Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
  British Journal of Cancer, 2004
• Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
  Cancer Chemotherapy and Pharmacology, 2000